0000000000542029

AUTHOR

Martin Röcken

0000-0003-3795-7001

showing 5 related works from this author

Diagnostics of autoimmune bullous diseases in German dermatology departments

2012

Summary Background: No consistent data are available on the currently employed diagnostic tools for autoimmune bullous diseases in Germany. The aim of this survey was to describe currently performed diagnostic methods for bullous autoimmune diseases in German dermatology departments. Methods: A standardized questionnaire evaluated the available diagnostic methods i. e. direct immunofluorescence microscopy (IFM), indirect IFM, commercial ELISA systems, and non-commercial serological tests as well as the number of samples per year in all 34 university and 39 non-university dermatology departments. Results: The overall return rate was 89 %, 100 % and 79 % for the university and non-university …

Pemphigoidmedicine.medical_specialtyDiagnostic methodsbusiness.industryDiagnostic testDermatologymedicine.diseaseDiagnostic toolsDermatologyhumanities3. Good healthSerology030207 dermatology & venereal diseases03 medical and health sciencesPemphigus0302 clinical medicine030220 oncology & carcinogenesisMedicineBullous pemphigoidbusinessDirect fluorescent antibodyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort…

2021

BackgroundCheckpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in part contradictory. The aims of this study were to develop a novel simple and rapid method that estimates pretreatment metastatic growth rate (MGR) and to investigate its prognostic impact in melanoma patients treated with antiprogrammed death receptor-1 (PD-1) antibodies.MethodsMGR was assessed in three independent cohorts of a total of 337 unselected consecutive metastasized stage IIIB–IV melanoma patients (discovery cohort: n=53, confirmation…

Male0301 basic medicineOncologyCancer ResearchSkin NeoplasmsTime Factors2437Programmed Cell Death 1 ReceptorPembrolizumabMetastasis0302 clinical medicineRisk FactorsImmunotherapy BiomarkersImmunology and Allergy1506Immune Checkpoint InhibitorsRC254-282MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle Agedddc:EuropeNivolumabTreatment OutcomeOncology030220 oncology & carcinogenesisCohortMolecular MedicineFemaleimmunotherapyNivolumabCohort studytumormedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemelanomamedicineHumansCell ProliferationNeoplasm StagingRetrospective StudiesPharmacologyProportional hazards modelbusiness.industrybiomarkersReproducibility of Resultsmedicine.disease030104 developmental biologyTomography X-Ray ComputedbusinessBrain metastasis
researchProduct

Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.

2019

Abstract Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antigenic specificities of tumor-infiltrating Tregs. We addressed this question by using a λ-MYC transgenic mouse model of endogenously arising B-cell lymphoma, which mirrors key features of human Burkitt lymphoma. We show that Foxp3+ Tregs suppress antitumor responses in endogenous lymphoma. Ablation of Foxp3+ Tregs significantly delayed tumor development. The ratio of Treg to effector T cells was elevated in growing tumors, which could be …

0301 basic medicineGenetically modified mouseCancer ResearchLymphoma B-CellImmunologychemical and pharmacologic phenomenaMice TransgenicT-Lymphocytes RegulatoryEpitope03 medical and health sciences0302 clinical medicineAntigenCell Line TumorMHC class ImedicineAnimalsAntigensbiologyEffectorFOXP3hemic and immune systemsmedicine.diseaseLymphomaMice Inbred C57BL030104 developmental biologyTumor Escape030220 oncology & carcinogenesisCancer researchbiology.proteinTumor EscapePeptidesCancer immunology research
researchProduct

Nutritional control of IL-23/Th17-mediated autoimmune disease through HO-1/STAT3 activation

2017

AbstractThe nutritional curcumin (CUR) is beneficial in cell-mediated autoimmune diseases. The molecular mechanisms underlying this food-mediated silencing of inflammatory immune responses are poorly understood. By investigating antigen-specific immune responses we found that dietary CUR impairs the differentiation of Th1/Th17 cells in vivo during encephalomyelitis and instead promoted Th2 cells. In contrast, feeding CUR had no inhibitory effect on ovalbumin-induced airway inflammation. Mechanistically, we found that CUR induces an anti-inflammatory phenotype in dendritic cells (DC) with enhanced STAT3 phosphorylation and suppressed expression of Il12b and Il23a. On the molecular level CUR …

0301 basic medicineSTAT3 Transcription FactorCurcuminEncephalomyelitis Autoimmune ExperimentalOvalbuminEncephalomyelitisInterleukin-23ArticleAutoimmune Diseases03 medical and health sciencesMiceImmune systemTh2 CellsmedicineInterleukin 23Gene silencingAnimalsPhosphorylationSTAT3Autoimmune diseaseInflammationImmunity CellularMultidisciplinarybiologyChemistryMembrane ProteinsDendritic Cellsmedicine.diseaseCell biologyHeme oxygenase030104 developmental biologybiology.proteinPhosphorylationTh17 CellsHeme Oxygenase-1Scientific Reports
researchProduct

Diagnostik blasenbildender Autoimmundermatosen an deutschen Hautkliniken

2012

DermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct